businesspress24.com - Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017
 

Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017

ID: 1506024

(firmenpresse) - EDMONTON, ALBERTA -- (Marketwired) -- 05/26/17 -- (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will provide a corporate update to on site shareholders on Thursday, June 1, 2017 at 8:30 a.m. MDT at the Westin Hotel, Edmonton, AB. The Company''s presentation will be followed by the Annual General and Special Meeting of Shareholders to be held at 10:00 a.m. MDT in the Devonian Room of the Westin Hotel. Shareholders are invited to breakfast prior to the meeting at 7:30 a.m. MDT.

As part of his presentation, Mr. Gagnon will provide a corporate overview and an update on the Company''s de-risked cosmeceuticals business. As part of the Company''s long-term strategic vision, Ceapro is developing its two pharmaceutical-grade active ingredient value drivers, avenanthramides and beta glucan, into different formulations to enable the transition into other sectors including nutraceuticals and pharmaceuticals.

Ceapro will post the presentation used during Mr. Gagnon''s prepared remarks for the corporate update on the Company''s website () on June 1, 2017.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company''s website at .





Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: Ceapro Inc.



Contacts:
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 908-938-1475

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Trillium Announces Proposed Public Offering
Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares
Bereitgestellt von Benutzer: Marketwired
Datum: 26.05.2017 - 06:05 Uhr
Sprache: Deutsch
News-ID 1506024
Anzahl Zeichen: 3476

contact information:
Contact person:
Town:

EDMONTON, ALBERTA


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 350 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017
"
steht unter der journalistisch-redaktionellen Verantwortung von

Ceapro Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ceapro Inc.



 

Who is online

All members: 10 562
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 74


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.